Valuation: Harvard Bioscience, Inc.

Market Cap 27.74M 24.25M 22.28M 20.77M 39.4M 2.64B 40M 268M 104M 1.3B 104M 102M 4.47B P/E 2026 *
-3.14x
P/E 2027 * -14x
Enterprise Value 27.74M 24.25M 22.28M 20.77M 39.4M 2.64B 40M 268M 104M 1.3B 104M 102M 4.47B EV / Sales 2026 *
0.31x
EV / Sales 2027 * 0.29x
Free-Float
90.52%
Yield 2026 *
-
Yield 2027 * -
1 day+1.65%
1 week+1.82%
1 month-5.38%
3 months+18.27%
6 months-5.66%
Current year-8.04%
1 week 5.9
Extreme 5.905
6.28
1 month 5.77
Extreme 5.7651
6.69
Current year 4
Extreme 4
7.5
1 year 3.76
Extreme 3.755
9.4
3 years 2.81
Extreme 2.813
58.8
5 years 2.81
Extreme 2.813
87.5
10 years 2.81
Extreme 2.813
87.5
Manager TitleAgeSince
Chief Executive Officer 55 28/07/2025
Director of Finance/CFO 63 12/05/2025
Chief Tech/Sci/R&D Officer - 01/04/2019
Director TitleAgeSince
Director/Board Member 56 17/12/2025
Director/Board Member 58 05/09/2025
Director/Board Member 52 16/07/2025
Date Insider Type Main position Quantity % Market Cap.
09/06Free

Director

16,556 0.3671%
09/06Free

Director

16,556 0.3671%
09/06Free

Director

16,556 0.3671%
Change 5-day change 1-year change 3-year change Capi.($)
+1.65%+1.82%+35.76%-88.88% 27.74M
+1.97%+2.03%+21.92%+0.83% 195B
+5.87%+5.27%-21.76%+26.78% 151B
+2.17%+0.89%-2.59%-16.42% 140B
+4.83%+2.06%-56.73%-15.69% 67.09B
+2.59%+3.95%+22.89%+3.15% 54.34B
+0.03%+2.19%-25.48%-31.00% 44.63B
+0.31%+1.30%+8.30%+43.25% 37.24B
-2.02%-3.91%+7.67%+9.53% 36.91B
+4.24%+4.66%-18.42%-2.34% 30.24B
Average +2.16%+2.78%-2.84%-7.08% 75.6B
Weighted average by Cap. +2.78%+3.44%-4.03%+2.02%

Financials

2026 *2027 *
Net sales 88.6M 77.45M 71.18M 66.35M 126M 8.44B 128M 855M 332M 4.15B 333M 325M 14.29B 94.2M 82.35M 75.68M 70.54M 134M 8.97B 136M 909M 353M 4.41B 354M 346M 15.19B
Net income -9.05M -7.91M -7.27M -6.78M -12.85M -862M -13.05M -87.29M -33.93M -424M -33.97M -33.24M -1.46B -2.05M -1.79M -1.65M -1.54M -2.91M -195M -2.96M -19.77M -7.69M -95.95M -7.69M -7.53M -331M
Net Debt - -
Logo Harvard Bioscience, Inc.
Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.
Employees
328
Date Price Change Volume
02/07/26 USD 6.150 +1.65% 9,575
01/07/26 USD 6.050 -1.63% 20,447
30/06/26 USD 6.150 +0.41% 23,387
29/06/26 USD 6.125 +1.41% 11,272
26/06/26 USD 6.040 +1.34% 7,919
Trader
-
Investor
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
6.150USD
Average target price
6.000USD
Spread / Average Target
-2.44%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. HBIO Stock